Study on Alpha/Beta T and B Cell Depletion with Zoledronic Acid for Treating Solid Tumors

Inclusion Criteria

• Patients must be 25 years old or younger.
• Have a solid tumor that has come back or not responded to treatment, and for which a previous transplant was not successful or not an option.
• Types of eligible tumors include:
  • High-risk neuroblastoma
  • Relapsed or refractory rhabdomyosarcoma
  • Certain types of soft tissue sarcomas
  • High-risk non-rhabdomyosarcoma soft tissue sarcomas
  • Other high-risk extracranial solid tumors
  • Relapsed or refractory bone tumors like osteosarcoma and Ewing sarcoma
  • Other high-risk solid tumors with less than 10% expected survival with standard treatment
• Must not have more than one active cancer at the time of joining the study.
• Must have a partially matched family donor for the transplant.
• Must be in relatively good health, with a performance score of 60% or higher.
• Must have adequate organ function, including:
  • Good lung function or no breathing problems
  • Good kidney function
  • Good heart function
• Must agree to use effective birth control during the study and for one year after the transplant.
• Must provide written consent to participate in the study.

Exclusion Criteria

• Cannot have an uncontrolled infection at the time of joining the study.
• Cannot have shown a lack of compliance with medical care.
• Cannot have had a previous allogeneic stem cell transplant within the last 6 months.
• Must have an eligible donor available for the transplant.
• Cannot have a life expectancy of less than 3 months.
• Must meet the organ function criteria.
• Cannot be pregnant or breastfeeding, and must agree to use birth control if of childbearing potential.
• Cannot have any other condition that might interfere with the study or increase the risk of complications.
• Cannot be a prisoner or involuntarily detained for treatment.